Stanley

A study conducted by researchers at the Fred Hutchinson Cancer Research Centre has showed that the experimental, living T-cell therapy has put patients with cancer in remission.

Patients with acute lymphoblastic leukemia, non-Hodgkin lymphoma and chronic lymphocytic leukemia have participated in the trial.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The patients, who were not expected to survive for more than a few months as their disease had previously relapsed or was resistant to other treatments, showed no signs of the disease.

The Juno Therapeutics-funded trial has been designed to test the safety of the latest iteration of an experimental immunotherapy, in which a patient’s own T cells are reprogrammed to eliminate cancer.

T cells are white blood cells that can detect foreign or abnormal cells, including cancerous ones.

The reprogramming involves genetically engineering the T cells with synthetic molecules called chimeric antigen receptors (CAR), which enable them to target and destroy tumour cells bearing a particular target.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"According to the ongoing study, 27 out of 29 patients with an advanced blood cancer experienced sustained remissions."

Fred Hutchinson Cancer Research Centre immunotherapy researcher Stanley Riddell said that progress now being made, underscored by these latest results, is finally making immunotherapy ‘a pillar of cancer therapy’.

According to the ongoing study, 27 out of 29 patients with an advanced blood cancer experienced sustained remissions.

Nearly 19 of 30 non-Hodgkin lymphoma patients experienced partial or complete responses, while 27 of 29 acute lymphoblastic leukaemia patients showed no trace of cancer in their bone marrow following their infusions.

"Much like chemotherapy and radiotherapy, it’s not going to be a save-all," Riddell added.

Image: Fred Hutchinson Cancer Research Centre immunotherapy researcher Stanley Riddell. Photo: courtesy of Fred Hutchinson Cancer Research Centre.